Amylyx Pharmaceuticals, Inc.
AMLX
Classement en actions
#4349
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Prix de l'action
$28.83
Capitalisation boursière
$3.62B
Changement (1 jour)
5.49%
Changement (1 an)
87.57%
Pays
US
Échange Amylyx Pharmaceuticals, Inc. (AMLX)
Catégorie
Healthcare
Ratio P/B pour Amylyx Pharmaceuticals, Inc. (AMLX)
Ratio P/B au October 2026 TTM : 12.57
Selon les derniers rapports financiers et le cours de l'action de Amylyx Pharmaceuticals, Inc., le ratio cours/valeur comptable actuel (TTM) est 12.57. À la fin de 2023, le ratio P/B était de 2.28.
Historique du ratio P/B pour Amylyx Pharmaceuticals, Inc. de 2019 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
